| Name | LB100 |
| Description | LB100 (LB-100) is a water soluble protein phosphatase 2A (PP2A) inhibitor. |
| Cell Research | Cytotoxicity is conducted by using a Cell Counting Kit-8. Cells are seeded in 96-well plates with a density of 3000 cells per well and are assessed after treatments following the CCK-8 protocol. Relative cytotoxicity is expressed as a percentage of speci?c controls. (Only for Reference) |
| Kinase Assay | PP2A activity assays: Cultured pancreatic cancer cells are treated with IC50 of LB-100 for each cell line or equal volume of vehicle for 2 hours, and PP2A activity assays are then performed using Ser/Thr phosphatase assay kit. Cells are lysed with an ultrasonic cell disruptor, and the PP2A concentration is measured using a Ser/Thr phosphatase assay kit according to the instructions. Assays for each cell line are performed in triplicate. |
| In vitro | In xenograft mouse models of pancreatic cancer, LB-100 (2 mg/kg, i.p.) enhances the therapeutic efficacy of the chemotherapy agent doxorubicin. LB-100 increases both the blood flow velocity on the tumor surface and the microvascular density of the tumor. |
| In vivo | Compared to the control group, LB-100 significantly increased the intracellular concentration of doxorubicin by approximately 2.5 times, enhancing the tumor cells' sensitivity to doxorubicin. Additionally, LB-100 amplified the secretion of vascular endothelial growth factor, thereby promoting angiogenesis mediated by HIF-1α-VEGF. LB-100 also demonstrated a notable inhibitory effect on the growth of BxPc-3 (IC50: 2.3 μM) and Panc-1 (IC50: 1.7 μM) cells. Following treatment with LB-100, a reduction of 30-50% in PP2A activity was observed in BxPc-3, SW1990, and Panc-1 tumor cells. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 67.5 mg/mL (251.57 mM), Sonication is recommended.
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | PP2A | LB100 |
| Inhibitors Related | β-Glycerophosphate disodium salt pentahydrate | Hexane-1,6-diol | 2-[dodecyl(2-hydroxyethyl)amino]ethanol | Idoxuridine | Cyclosporine | Tartaric acid disodium dihydrate | Stearic acid | CaMKP Inhibitor | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | L-Ascorbic acid 2-phosphate | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | Anti-Obesity Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
